Literature DB >> 10911818

Infection control in cystic fibrosis: methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and the Burkholderia cepacia complex.

J R Govan1.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10911818      PMCID： PMC1305883     

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  50 in total

1.  Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium.

Authors:  D A Henry; M E Campbell; J J LiPuma; D P Speert
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

Review 2.  Should patients with cystic fibrosis infected with Burkholderia cepacia undergo lung transplantation?

Authors:  A K Webb; J Egan
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

3.  Strategies for the management of healthcare staff colonized with epidemic methicillin-resistant Staphylococcus aureus.

Authors:  R A Cox; C Conquest
Journal:  J Hosp Infect       Date:  1997-02       Impact factor: 3.926

4.  Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis.

Authors:  E Mahenthiralingam; D A Simpson; D P Speert
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

5.  When should healthcare workers be screened for methicillin-resistant Staphylococcus aureus?

Authors:  M P Lessing; J Z Jordens; I C Bowler
Journal:  J Hosp Infect       Date:  1996-11       Impact factor: 3.926

6.  Epidemiology of Pseudomonas aeruginosa in cystic fibrosis and the possible role of contamination by dental equipment.

Authors:  E T Jensen; B Giwercman; B Ojeniyi; J M Bangsborg; A Hansen; C Koch; N E Fiehn; N Høiby
Journal:  J Hosp Infect       Date:  1997-06       Impact factor: 3.926

7.  Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov.

Authors:  P Vandamme; B Holmes; M Vancanneyt; T Coenye; B Hoste; R Coopman; H Revets; S Lauwers; M Gillis; K Kersters; J R Govan
Journal:  Int J Syst Bacteriol       Date:  1997-10

Review 8.  Burkholderia cepacia: medical, taxonomic and ecological issues.

Authors:  J R Govan; J E Hughes; P Vandamme
Journal:  J Med Microbiol       Date:  1996-12       Impact factor: 2.472

9.  Burkholderia (Pseudomonas) cepacia epidemiology in a cystic fibrosis population: a genome finger-printing study.

Authors:  G Cazzola; G Amalfitano; E Tonolli; C Perazzoli; I Piacentini; G Mastella
Journal:  Acta Paediatr       Date:  1996-05       Impact factor: 2.299

10.  Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.

Authors:  K Cheng; R L Smyth; J R Govan; C Doherty; C Winstanley; N Denning; D P Heaf; H van Saene; C A Hart
Journal:  Lancet       Date:  1996-09-07       Impact factor: 79.321
View more
  10 in total

Review 1.  Recent advances in cross-infection in cystic fibrosis: Burkholderia cepacia complex, Pseudomonas aeruginosa, MRSA and Pandoraea spp.

Authors:  Andrew M Jones; A Kevin Webb
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

2.  2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings.

Authors:  Jane D Siegel; Emily Rhinehart; Marguerite Jackson; Linda Chiarello
Journal:  Am J Infect Control       Date:  2007-12       Impact factor: 2.918

3.  Molecular epidemiology of Pseudomonas aeruginosa in cystic fibrosis patients from Southeast Austria.

Authors:  Lilian Masoud-Landgraf; Alexandra Badura; Ernst Eber; Gebhard Feierl; Josefa Posch; Gernot Zarfel; Maximilian Zach; Egon Marth
Journal:  Wien Klin Wochenschr       Date:  2012-04-21       Impact factor: 1.704

4.  Persistence of Burkholderia multivorans within the pulmonary macrophage in the murine lung.

Authors:  Karen K Chu; Kelly L MacDonald; Donald J Davidson; David P Speert
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

5.  PCR-based detection of a cystic fibrosis epidemic strain of Pseudomonas Aeruginosa.

Authors:  Stavroula Panagea; Craig Winstanley; Yasmin N Parsons; Martin J Walshaw; Martin J Ledson; C Anthony Hart
Journal:  Mol Diagn       Date:  2003

6.  Can patients with cystic fibrosis have a career in the health service?

Authors:  T J David
Journal:  J R Soc Med       Date:  2002-06       Impact factor: 18.000

7.  Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study.

Authors:  Daniel Hind; Sarah J Drabble; Madelynne A Arden; Laura Mandefield; Simon Waterhouse; Chin Maguire; Hannah Cantrill; Louisa Robinson; Daniel Beever; Alexander J Scott; Sam Keating; Marlene Hutchings; Judy Bradley; Julia Nightingale; Mark I Allenby; Jane Dewar; Pauline Whelan; John Ainsworth; Stephen J Walters; Alicia O'Cathain; Martin J Wildman
Journal:  BMC Pulm Med       Date:  2019-04-11       Impact factor: 3.317

8.  Staphylococcus aureus autoinducer-2 quorum sensing decreases biofilm formation in an icaR-dependent manner.

Authors:  Dan Yu; Liping Zhao; Ting Xue; Baolin Sun
Journal:  BMC Microbiol       Date:  2012-12-05       Impact factor: 3.605

9.  Analysis and Characterization of Staphylococcus aureus Small Colony Variants Isolated From Cystic Fibrosis Patients in Austria.

Authors:  Lilian Masoud-Landgraf; Gernot Zarfel; Tanja Kaschnigg; Simone Friedl; Gebhard Feierl; Ute Wagner-Eibel; Ernst Eber; Andrea J Grisold; Clemens Kittinger
Journal:  Curr Microbiol       Date:  2016-01-28       Impact factor: 2.188

10.  Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation.

Authors:  Daniel Hind; Sarah J Drabble; Madelynne A Arden; Laura Mandefield; Simon Waterhouse; Chin Maguire; Hannah Cantrill; Louisa Robinson; Daniel Beever; Alex Scott; Sam Keating; Marlene Hutchings; Judy Bradley; Julia Nightingale; Mark I Allenby; Jane Dewar; Pauline Whelan; John Ainsworth; Stephen J Walters; Martin J Wildman; Alicia O'Cathain
Journal:  BMJ Open       Date:  2020-10-27       Impact factor: 2.692
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.